Epid-28. years of life lost for brain and other central nervous system tumors in the united states, 2018

Abstract Brain and other central nervous system tumors (BTs) contribute disproportionately to cancer morbidity and mortality relative to their incidence. To estimate the national burden due to these tumors in the United States (US), we estimated Years of Life Lost (YLL) due to premature death from BT overall and specific histopathologies. Mortality data for malignant and non-malignant BT were obtained from the National Vital Statistics System (~100% of US); survival data were obtained from the CDC’s National Program of Cancer Registries (NPCR, ~82% of the US) Survival Analytic Dataset for the years 2004-2018. YLL was calculated by adding estimated years of life left at their age of death. Mean YLL (mYLL) with corresponding 95% confidence intervals (95%CI) were reported by behavior, age at death, sex, and race/ethnicity for each data source, and by histopathology for NPCR. Total YLL due to malignant BT was 4,913,397 (mYLL=22.0) and 3,253,999 (mYLL=22.4), while non-malignant BTs contributed 208,278 YLL (mYLL=14.2). Females (mYLL=22.5), Hispanic individuals (mYLL=30.7), and children aged 0-14 years (mYLL=71.6), had the greatest mYLL due to malignant BTs. Glioblastoma had the highest total YLL (62.2% of all YLL, mYLL=19.8), while atypical teratoid/rhabdoid tumors had the greatest mYLL despite accounting for less than 1% of total YLL due to malignant BT (mYLL=74.4). Meningiomas accounted for 79% of total YLL due to non-malignant tumors, with a mYLL of 13.7. Compared to non-malignant BT, malignant BTs have the greatest mYLL, reflecting their short survival time post-diagnosis. BT are the most common type of cancer in children, leading to relatively high total (475,290 YLL) and mYLL for pediatric BT which may contribute substantially to cancer-specific mortality in this population. These estimates provide a compliment to other population-based BT statistics in demonstrating the impact of these debilitating tumors.